TESLAC
LOE ApproachingNDAORALTABLET
Approved
May 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TESLAC is an oral small-molecule tablet approved in 1970 by Bristol Myers Squibb as a legacy NDA product. The specific mechanism of action and indications are not publicly documented in available data, indicating this is a long-established agent with historical rather than contemporary market prominence.
LOE Approaching
This product is approaching loss of exclusivity with minimal linked job openings, suggesting a small, stable team focused on legacy brand maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TESLAC has zero linked job openings and represents a mature legacy product with minimal career growth potential. Career moves to this product typically involve stewardship roles suited to professionals seeking stability over innovation or rapid advancement.
Brand ManagerField Sales Representative
Worked on TESLAC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.